Director Clyde Hosein buys 6,500 shares of XRAY at $9.98; 4 other insiders bought within 14 days amid -3.0% revenue decline, unprofitable year.
Clyde Hosein purchased 6,500 shares at $9.98 on 2026-06-15, increasing his holdings by 10.1% from 64.1K to 70.6K shares. This transaction is part of a cluster pattern: 4 other insiders also bought within the past 14 days, suggesting coordinated internal interest despite operating headwinds. The company reported net income of $-10.0M on revenue of $880.0M in its latest quarter, with annual revenue growth of -3.0%, indicating the firm is unprofitable and contracting. The stock currently trades at $10.45, down 38.8% from its 52-week high of $17.09, creating a significant valuation gap that may be attracting director-level accumulation at depressed levels.